Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

Telli, Melinda L; Timms, Kirsten M; Reid, Julia; Hennessy, Bryan; Mills, Gordon B; Jensen, Kristin C; Szallasi, Zoltan; Barry, William T; Winer, Eric P; Tung, Nadine M; Isakoff, Steven J; Ryan, Paula D; Greene-Colozzi, April; Gutin, Alexander; Sangale, Zaina; Iliev, Diana; Neff, Chris; Abkevich, Victor; Jones, Joshua T; Lanchbury, Jerry S; Hartman, Anne-Renee; Garber, Judy E; Ford, James M; Silver, Daniel P; Richardson, Andrea L

Telli, Melinda L; Timms, Kirsten M; Reid, Julia; Hennessy, Bryan; Mills, Gordon B; Jensen, Kristin C; Szallasi, Zoltan; Barry, William T; Winer, Eric P; Tung, Nadine M; Isakoff, Steven J; Ryan, Paula D; Greene-Colozzi, April; Gutin, Alexander; Sangale, Zaina; Iliev, Diana; Neff, Chris; Abkevich, Victor; Jones, Joshua T; Lanchbury, Jerry S; Hartman, Anne-Renee; Garber, Judy E; Ford, James M; Silver, Daniel P; Richardson, Andrea L.

Affiliation

Telli ML; Stanford University School of Medicine, Stanford, California.
Timms KM; Myriad Genetics Inc., Salt Lake City, Utah.
Reid J; Myriad Genetics Inc., Salt Lake City, Utah.
Hennessy B; University of Texas MD Anderson Cancer Center, Houston, Texas.
Mills GB; University of Texas MD Anderson Cancer Center, Houston, Texas.
Jensen KC; Stanford University School of Medicine, Stanford, California.
Szallasi Z; Denmark Technical University, Lyngby, Denmark. Children's Hospital Boston, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
Barry WT; Harvard Medical School, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, Massachusetts.
Winer EP; Harvard Medical School, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, Massachusetts.
Tung NM; Harvard Medical School, Boston, Massachusetts. Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Isakoff SJ; Harvard Medical School, Boston, Massachusetts. Massachusetts General Hospital, Boston, Massachusetts.
Ryan PD; Massachusetts General Hospital, Boston, Massachusetts.
Greene-Colozzi A; Dana-Farber Cancer Institute, Boston, Massachusetts.
Gutin A; Myriad Genetics Inc., Salt Lake City, Utah.
Sangale Z; Myriad Genetics Inc., Salt Lake City, Utah.
Iliev D; Myriad Genetics Inc., Salt Lake City, Utah.
Neff C; Myriad Genetics Inc., Salt Lake City, Utah.
Abkevich V; Myriad Genetics Inc., Salt Lake City, Utah.
Jones JT; Myriad Genetics Inc., Salt Lake City, Utah.
Lanchbury JS; Myriad Genetics Inc., Salt Lake City, Utah.
Hartman AR; Myriad Genetics Inc., Salt Lake City, Utah.
Garber JE; Harvard Medical School, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, Massachusetts.
Ford JM; Stanford University School of Medicine, Stanford, California.
Silver DP; Harvard Medical School, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, Massachusetts. Daniel_Silver@DFCI.Harvard.Edu.
Richardson AL; Harvard Medical School, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, Massachusetts. Brigham and Women's Hospital, Boston, Massachusetts.

Clin Cancer Res ; 22(15): 3764-73, 2016 08 01.

Article de En | MEDLINE | ID: mdl-26957554

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protocoles de polychimiothérapie antinéoplasique / Télomère / Perte d'hétérozygotie / Déséquilibre allélique / Recombinaison homologue / Tumeurs du sein triple-négatives Type d'étude: Etiology_studies / Prognostic_studies / Risk_factors_studies Limites: Female / Humans Langue: En Journal: Clin Cancer Res Sujet du journal: NEOPLASIAS Année: 2016 Type de document: Article

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google